Synbio International, Inc. (OTC: SYIN) has taken a significant step toward generating revenue by entering into a Strategic Licensing, Manufacturing, Supply and Revenue Sharing Agreement with MD PHD Wellness, Inc. The deal grants Synbio exclusive rights to commercialize MD PHD Wellness' proprietary nutraceutical formulations across the United States and Canada. This move allows Synbio to bypass the costly and time-intensive process of developing products from scratch, providing an immediate pathway to market.
The agreement covers MD PHD Wellness' flagship anti-anxiety nutraceutical formulation, which will be marketed under Synbio's Healing Force™ brand. It also establishes a framework for evaluating and commercializing additional wellness products in the future, ensuring a long-term product pipeline. Under the terms, MD PHD Wellness will handle product development, manufacturing, quality assurance, and supply chain management, while Synbio will manage branding, marketing, sales, and distribution. Profits will be shared after recovery of approved manufacturing and commercialization costs.
Claudio Solitario, CEO of Synbio International, called the agreement a "transformational milestone" that combines MD PHD's expertise with Synbio's commercialization capabilities. He emphasized that the partnership gives Synbio immediate access to products that can generate near-term revenue while allowing management to focus on building brands and expanding market presence. Solitario also highlighted the efficiency of the model, positioning Synbio to participate in the rapidly expanding global nutraceutical market while continuing to advance its AI-driven healthcare technologies.
The scientific leadership behind MD PHD Wellness adds credibility to the venture. Co-founder Dr. Robert Lawrence holds two Ph.D.s in Nuclear Physics and Biomedical Engineering, with a career spanning medicine, biomedical engineering, and nutraceutical development. His research includes innovations in cellular regeneration and natural product delivery systems. Co-founder Dr. David Anderson, an experienced physician and researcher, played a key role in developing the licensed formulations. His background includes service as a Research Physician and Senior Research Scientist at a prominent New York-based university, where he participated in evaluating therapeutics and nutraceuticals. Anderson has been recognized in Marquis Who's Who for his professional achievements.
This agreement aligns with Synbio's broader strategy of building a diversified healthcare company. The company pairs near-term revenue from commercial wellness products with longer-term value creation from its AI-driven mental health technologies. Synbio is focused on clinically validating an AI-driven software that screens for mental health conditions using facial analysis. The nutraceutical line is expected to generate early revenue while the software advances through validation, with products sold directly to consumers online starting in 2026.
The global nutraceutical market continues to expand, and this partnership positions Synbio to capitalize on that growth. By leveraging MD PHD Wellness's scientific expertise and manufacturing capabilities, Synbio can enter the market with proprietary, scientifically developed products. The dual-track approach of combining nutraceutical revenue with AI technology development provides multiple avenues for growth and establishes a recurring revenue stream that can support continued innovation.
For more information about Synbio International, visit their website at http://www.synbiointl.com.
